ThinkCyte Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
50
- Latest Deal Type
-
2ndary - Private
- Investors
-
25
ThinkCyte General Information
Description
Developer of an image-based cell sorting technology designed to advance single-cell analysis for research, diagnostics, and therapeutics. The company's ghost cytometry technology integrates advanced optics, machine learning, and biotechnology and brings ultra-high throughput, content-rich analysis, and sorting on a single-cell level to disciplines such as drug discovery, cell therapy, and clinical diagnostics, enabling medical researchers to identify cells based on their images and isolate target cells, including rare cells, in real-time.
Contact Information
Website
www.thinkcyte.comCorporate Office
- 3-18-14 Hongo, Bunkyo-ku
- Tokyo, 113-0033
- Japan
Corporate Office
- 3-18-14 Hongo, Bunkyo-ku
- Tokyo, 113-0033
- Japan
ThinkCyte Timeline
ThinkCyte Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 11. Later Stage VC | 11-Nov-2025 | Completed | Generating Revenue | |||
| 10. Later Stage VC (Series C) | 29-Aug-2024 | Completed | Generating Revenue | |||
| 9. Grant | 01-Sep-2023 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series B) | 19-May-2021 | Completed | Generating Revenue | |||
| 7. Grant | 24-Aug-2020 | Completed | Generating Revenue | |||
| 6. Early Stage VC (Series A) | 29-May-2020 | Completed | Generating Revenue | |||
| 5. Accelerator/Incubator | 24-Jun-2019 | Completed | Startup | |||
| 4. Seed Round | 26-Apr-2019 | $6.27M | $9.6M | Completed | Startup | |
| 3. Accelerator/Incubator | 26-Nov-2018 | $3.28M | Completed | Startup |
ThinkCyte Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Class D Preferred | ||||||||
| Class C Preferred | ||||||||
| Class B Preferred | ||||||||
| Class A-2 Preferred | ||||||||
| Class A-1 Preferred | 742,800 | $4.54 | $4.54 | 1x | $4.54 | 5.94% | ||
| Class A Preferred | 1,011,100 | $3.09 | $3.09 | 1x | $3.09 | 8.09% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
ThinkCyte Comparisons
Industry
Financing
Details
ThinkCyte Competitors (7)
One of ThinkCyte’s 7 competitors is Cytomos, a Venture Capital-Backed company based in Edinburgh, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cytomos | Venture Capital-Backed | Edinburgh, United Kingdom | ||||
| Deepcell | Venture Capital-Backed | Menlo Park, CA | ||||
| Immunai | Venture Capital-Backed | New York, NY | ||||
| Ozette | Venture Capital-Backed | Seattle, WA | ||||
| Lightcast (Biotechnology) | Venture Capital-Backed | Cambridge, United Kingdom |
ThinkCyte Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ThinkCyte Patents
ThinkCyte Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2026519407-A | A machine learning-based sample classifier system and method for physical samples | Pending | 28-Apr-2023 | ||
| JP-2024130271-A | Tip for observation | Pending | 14-Mar-2023 | ||
| JP-7884265-B2 | Optical systems and specimen analyzers | Active | 02-Nov-2022 | ||
| JP-2023067851-A | Cell maturity evaluation method | Pending | 29-Oct-2021 | ||
| WO-2023062830-A1 | Flow cytometer, imaging device, position detection method, and program | Inactive | 15-Oct-2021 | G01N15/1409 |
ThinkCyte Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ThinkCyte Investors (25)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Japan Investment Adviser | PE/Buyout | Minority | ||
| Mitsui Sumitomo Kaijo Capital | Corporate Venture Capital | Minority | ||
| Global Brain | Venture Capital | Minority | ||
| Japan Green Investment Corporation for Carbon Neutrality | Government | Minority | ||
| Japan Growth Capital Investment Corporation | Venture Capital | Minority |
ThinkCyte FAQs
-
When was ThinkCyte founded?
ThinkCyte was founded in 2016.
-
Where is ThinkCyte headquartered?
ThinkCyte is headquartered in Tokyo, Japan.
-
What is the size of ThinkCyte?
ThinkCyte has 50 total employees.
-
What industry is ThinkCyte in?
ThinkCyte’s primary industry is Diagnostic Equipment.
-
Is ThinkCyte a private or public company?
ThinkCyte is a Private company.
-
What is ThinkCyte’s current revenue?
The current revenue for ThinkCyte is .
-
How much funding has ThinkCyte raised over time?
ThinkCyte has raised $84.7M.
-
Who are ThinkCyte’s investors?
Japan Investment Adviser, Mitsui Sumitomo Kaijo Capital, Global Brain, Japan Green Investment Corporation for Carbon Neutrality, and Japan Growth Capital Investment Corporation are 5 of 25 investors who have invested in ThinkCyte.
-
Who are ThinkCyte’s competitors?
Cytomos, Deepcell, Immunai, Ozette, and Lightcast (Biotechnology) are some of the 7 competitors of ThinkCyte.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
